Clinical Trial Update: Study of AZD2811 + Durvalumab in ES-SCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of AZD2811 and durvalumab for extensive-stage small cell lung cancer is active/not recruiting, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• AZD2811
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Small-Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-27